南京正大天晴制药有限公司

About 南京正大天晴制药有限公司

Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. was founded in 2001, jointly invested and established by two major shareholders, Chia Tai Group of Thailand and Jiangsu Provincial Land Reclamation. It has now developed into a comprehensive top 100 chemical pharmaceutical enterprise in China with "drug research and development, production, and sales" as one entity, covering therapeutic areas such as cardiovascular and cerebrovascular diseases, tumors, surgical perioperative care, contrast agents, digestion, and urinary system. Research and development as the foundation, innovation-driven. The company adheres to the R&D philosophy of "combining imitation and innovation, with both internal and external efforts." Relying on R&D investment several times the industry average and a research and development team of nearly 400 experts, the company's R&D strength has reached the forefront of the country. Currently, 4-6 new products are approved annually, with more than 100 products under development, covering innovative drugs, sustained-release and controlled-release preparations, and characteristic generic drugs. Supported by international cooperation and postdoctoral research stations, it continuously injects innovative vitality into the company's development. Marketing promotion, accelerating competitiveness. Since its operation, the company's sales have achieved an average annual compound growth rate of 30%, far exceeding the industry average. Based on nearly 20 years of deep cultivation in advantageous fields such as cardiovascular and cerebrovascular diseases, tumors, and surgery, combined with the expansion of emerging fields like perioperative care and contrast agents, through the professional leadership of the market medical system and the professional promotion by over 2000 academic teams, it currently covers the three major markets of "hospitals, pharmacies, and the internet." Core products in fields like cardiovascular and cerebrovascular diseases, tumors, and surgery achieve tens of millions of patient benefits annually, holding a leading market share in their respective fields! Strength forging, honor witnessing. Driven by the "dual engines of R&D and marketing," the company is expanding upstream to raw materials and downstream to comprehensive disease management centered on patients. Coupled with scientific and standardized management and continuously upgraded intelligent manufacturing, it continuously promotes the company's healthy, sustainable, and rapid development. It has successively won honors such as "National Torch Plan Key High-tech Enterprise," "National Excellent Enterprise for Scientific and Technological Innovation," "National Demonstration Enterprise for Drug Quality Integrity Construction," "National Enterprise Abiding by Contracts and Valuing Credit," "Jiangsu Provincial May Day Labor Medal," and "Jiangsu Provincial Demonstration Enterprise for the Integration of Informatization and Industrialization." Looking to the future, writing a new chapter. With the full operation of the new pharmaceutical industrial park, with a total investment of over 2 billion yuan, integrating functions such as "strategic headquarters, R&D innovation, formulation intelligent manufacturing, and training empowerment," the company's new journey towards becoming a leading enterprise in the industry has begun. Nanjing Chia Tai Tianqing will continue to exert its efforts in core areas to benefit more patients, thereby practicing the business purpose of "Healthy Humanity, Creating a Better Future!"